Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma Meeting Abstract

  

Authors:	Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; Scordo, M.; Chung, D.; Landau, H.; Giralt, S.; Lesokhin, A.; Korde, N.; Lin, D.; Wu, B.; Fowler, J.; Fernandez, M.; Kim, N.; Doyle, M.; Hester, L.; Orozco, J.; Usmani, S.
Abstract Title:	Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
Meeting Title:	21st Annual Meeting and Exposition of the International Myeloma Society
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	24
Issue:	Suppl. 2
Meeting Dates:	2024 Sep 25-28
Meeting Location:	Rio de Janeiro, Brazil
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2024-09-01
Start Page:	S91
End Page:	S92
Language:	English
ACCESSION:	WOS:001325737900149
PROVIDER:	wos
DOI:	10.1016/S2152-2650(24)01989-X
Notes:	Meeting Abstract: P-086 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/221051